206 related articles for article (PubMed ID: 11872034)
1. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
[TBL] [Abstract][Full Text] [Related]
2. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
Mulhall JP; Bukofzer S; Edmonds AL; George M;
Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
Dula E; Bukofzer S; Perdok R; George M;
Eur Urol; 2001 May; 39(5):558-3; discussion 564. PubMed ID: 11464037
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
Dula E; Keating W; Siami PF; Edmonds A; O'neil J; Buttler S
Urology; 2000 Jul; 56(1):130-5. PubMed ID: 10869641
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine: an update of clinical trial results.
Heaton JP
Int J Impot Res; 2000 Oct; 12 Suppl 4():S67-73. PubMed ID: 11035390
[TBL] [Abstract][Full Text] [Related]
6. Oral treatment of erectile dysfunction with apomorphine SL.
Altwein JE; Keuler FU
Urol Int; 2001; 67(4):257-63. PubMed ID: 11741126
[TBL] [Abstract][Full Text] [Related]
7. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings.
Riley A; Main M; Morgan F
J Sex Med; 2010 Apr; 7(4 Pt 1):1508-17. PubMed ID: 19845547
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury.
Strebel RT; Reitz A; Tenti G; Curt A; Hauri D; Schurch B
BJU Int; 2004 Jan; 93(1):100-4. PubMed ID: 14678378
[TBL] [Abstract][Full Text] [Related]
9. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
Pavone C; Curto F; Anello G; Serretta V; Almasio PL; Pavone-Macaluso M
J Urol; 2004 Dec; 172(6 Pt 1):2347-9. PubMed ID: 15538264
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study.
Caruso S; Intelisano G; Farina M; DiMari L; Agnello C; Giammusso B
Urology; 2003 Nov; 62(5):922-7. PubMed ID: 14624921
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men.
Gontero P; D'Antonio R; Pretti G; Fontana F; Panella M; Kocjancic E; Allochis G; Frea B
Int J Impot Res; 2005; 17(1):80-5. PubMed ID: 15510184
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates.
Fagan TC; Buttler S; Marbury T; Taylor A; Edmonds A;
Am J Cardiol; 2001 Oct; 88(7):760-6. PubMed ID: 11589843
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
[TBL] [Abstract][Full Text] [Related]
14. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.
Hatzichristou DG; Aliotta P; Auerbach S; Barkin J; Lording D; Murdock M; Wilkins HJ; McBride TA; Colopy MW; Carson CC;
Clin Ther; 2005 Sep; 27(9):1452-61. PubMed ID: 16291418
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of apomorphine SL (Ixense (TM) ).
Montorsi F
Int J Impot Res; 2003 Apr; 15 Suppl 2():S7-9. PubMed ID: 12825097
[TBL] [Abstract][Full Text] [Related]
16. Evaluating dose regimens of apomorphine, an open-label study.
Kongkanand A; Opanuraks J; Tantiwongse K; Choeypunt N; Tantiwong A; Amornvejsukit T
Int J Impot Res; 2003 Apr; 15 Suppl 2():S10-2. PubMed ID: 12825098
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of apomorphine SL (Uprima).
Bukofzer S; Livesey N
Int J Impot Res; 2001 Aug; 13 Suppl 3():S40-4. PubMed ID: 11477491
[TBL] [Abstract][Full Text] [Related]
18. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial.
Montorsi F; Padma-Nathan H; Buvat J; Schwaibold H; Beneke M; Ulbrich E; Bandel TJ; Porst H;
J Sex Med; 2004 Sep; 1(2):168-78. PubMed ID: 16422971
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study.
Kongkanand A; Ratana-Olarn K; Ruangdilokrat S; Tantiwong A;
J Med Assoc Thai; 2003 Mar; 86(3):195-205. PubMed ID: 12757058
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder.
Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Cianci A
Urology; 2004 May; 63(5):955-9. PubMed ID: 15134988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
